Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Terminated
1(9%)

Phase Distribution

Ph not_applicable
4
36%
Ph phase_1
2
18%
Ph phase_4
1
9%
Ph phase_2
1
9%
Ph phase_3
2
18%

Phase Distribution

2

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution10 total trials
Phase 1Safety & dosage
2(20.0%)
Phase 2Efficacy & side effects
1(10.0%)
Phase 3Large-scale testing
2(20.0%)
Phase 4Post-market surveillance
1(10.0%)
N/ANon-phased studies
4(40.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(4)
Terminated(1)
Other(6)

Detailed Status

unknown6
Completed4
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
80.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (20.0%)
Phase 21 (10.0%)
Phase 32 (20.0%)
Phase 41 (10.0%)
N/A4 (40.0%)

Trials by Status

terminated19%
unknown655%
completed436%

Recent Activity

Clinical Trials (11)

Drug Details

Intervention Type
DRUG
Total Trials
11